Brain Oxygen Optimization in Severe TBI, Phase 3
Key facts
- Who runs it
- University of Michigan
- Where
- Albuquerque, Ann Arbor, Atlanta, Aurora, Baltimore, Boston, Camden, Chapel Hill, Chicago, Cincinnati, Columbus, Dallas, Detroit, Durham, Flushing, Gainesville, Honolulu, Houston, Indianapolis, Los Angeles, Manhasset, Milwaukee, Morgantown, New Haven, New York, Palo Alto, Philadelphia, Pittsburgh, Portland, Richmond, Rochester, Sacramento, Saint Paul, Salt Lake City, San Antonio, San Francisco, Seattle, Syracuse, The Bronx, and Worcester, United StatesSee the 48 sitesAlso in 1 other country, 3 sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 1,094 people, planned
- Started
- 28 Aug 2019
- Expected to end
- 1 Nov 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- ICP + PbtO2 guided management strategy
- ICP guided management strategy
- Record updated
- 12 November 2026
Who can take part
- Age
- 14 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 22 criteriaShow less
Who can take part
- Non-penetrating traumatic brain injury
- Glasgow Coma Scale (GCS) 3-8 measured off paralytics
- Glasgow Coma Scale motor score < 6 if endotracheally intubated
- Evidence of intracranial trauma on CT scan
- Able to place intracranial probes and randomize within 6 hours of arrival at enrolling hospital
- Able to place intracranial probes and randomize within 12 hours from injury
- Age greater than or equal to 14 years
Who cannot take part
- Bilaterally absent pupillary response in the absence of paralytic medication
- Treatment of brain tissue oxygen values prior to randomization
- Known inability to perform activities of daily living (ADL) without assistance prior to injury
- Known active drug or alcohol dependence that, in the opinion of site investigator, would interfere with physiological response to brain tissue oxygen treatments
- Known pre-existing neurologic disease with confounding residual neurological deficits
- Non-survivable injury
- Contraindication to the placement of intracranial probes
- Planned use of devices which may unblind treating physicians to brain tissue hypoxia
- Systemic sepsis at screening
- Refractory hypotension
- Refractory systemic hypoxia
- PaO2/FiO2 ratio < 150
- Pregnancy
- Prisoner
- On EFIC Opt-Out list as indicated by a bracelet or medical alert
Where in United States
Also in 1 other country, 3 sites
- University of New Mexico HospitalAlbuquerque, United States
- University of MichiganAnn Arbor, United States
- Grady Memorial HospitalAtlanta, United States
- University of Colorado HospitalAurora, United States
- Johns Hopkins HospitalBaltimore, United States
- University of Maryland Medical CenterBaltimore, United States
- Beth Israel Deaconess Medical CenterBoston, United States
- Brigham and Women's HospitalBoston, United States
- Massachusetts General HospitalBoston, United States
- Cooper University HospitalCamden, United States
- University of North Carolina Medical CenterChapel Hill, United States
- University of Chicago Medical CenterChicago, United States
- University of Cincinnati Medical CenterCincinnati, United States
- OSU Wexner Medical CenterColumbus, United States
- Riverside Methodist HospitalColumbus, United States
- Parkland HospitalDallas, United States
- Detroit Receiving HospitalDetroit, United States
- Henry Ford HospitalDetroit, United States
- Duke University HospitalDurham, United States
- NewYork-Presbyterian: Queens HospitalFlushing, United States
- UF Health Shands HospitalGainesville, United States
- The Queen's Medical CenterHonolulu, United States
- Ben Taub General HospitalHouston, United States
- St Vincent HospitalIndianapolis, United States
- Cedars-Sinai Medical CenterLos Angeles, United States
- Ronald Reagan UCLA Medical CenterLos Angeles, United States
- North Shore University HospitalManhasset, United States
- Froedtert HospitalMilwaukee, United States
- WVU Healthcare Ruby Memorial HospitalMorgantown, United States
- Yale New Haven HospitalNew Haven, United States
- NYP Columbia University Medical CenterNew York, United States
- Stanford University Medical CenterPalo Alto, United States
- Penn Presbyterian Medical CenterPhiladelphia, United States
- Thomas Jefferson University HospitalPhiladelphia, United States
- UPMC Presbyterian HospitalPittsburgh, United States
- Maine Medical CenterPortland, United States
- Oregon Health & Science University HospitalPortland, United States
- VCU Medical CenterRichmond, United States
- Strong Memorial HospitalRochester, United States
- UC Davis Medical CenterSacramento, United States
- Regions HospitalSaint Paul, United States
- University of Utah HealthcareSalt Lake City, United States
- University of Texas Health Science Center San AntonioSan Antonio, United States
- San Francisco General HospitalSan Francisco, United States
- Harborview Medical CenterSeattle, United States
- SUNY Upstate Medical UniversitySyracuse, United States
- Jacobi Medical CenterThe Bronx, United States
- Umass Memorial Medical CenterWorcester, United States
About the trial
What the trial wants to find out
BOOST3 is a randomized clinical trial to determine the comparative effectiveness of two strategies for monitoring and treating patients with traumatic brain injury (TBI) in the intensive care unit (ICU). The study will determine the safety and efficacy of a strategy guided by treatment goals based on both intracranial pressure (ICP) and brain tissue oxygen (PbtO2) as compared to a strategy guided by treatment goals based on ICP monitoring alone. Both of these alternative strategies are used in standard care. It is unknown if one is more effective than the other. In both strategies the monitoring and goals help doctors adjust treatments including the kinds and doses of medications and the amount of intravenous fluids given, ventilator (breathing machine) settings, need for blood transfusions, and other medical care. The results of this study will help doctors discover if one of these methods is more safe and effective.
The 2 groups in the trial
- ICP onlyExisting treatment, for comparison
ICP guided management strategy: Care in the ICU of research participants randomized to this arm will be guided by a monitoring and treatment strategy in which doctors try to prevent high intracranial pressure (ICP) caused by a swollen brain. This strategy is one of two alternative strategies that is currently used in standard care of patients with traumatic brain injury.
Treatment: ICP guided management strategy
- ICP + PbtO2Existing treatment, for comparison
ICP + PbtO2 guided management strategy: Care in the ICU of research participants randomized to this arm will be guided by a monitoring and treatment strategy in which doctors try to prevent high intracranial pressure (ICP), and also try to prevent low PbtO2 (brain tissue oxygen levels). This strategy is one of two alternative strategies that is currently used in standard care of patients with traumatic brain injury.
Treatment: ICP + PbtO2 guided management strategy
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Brain Oxygen Optimization in Severe TBI (BOOST3): A Comparative Effectiveness Study to Test the Efficacy of a Prescribed Treatment Protocol Based on Monitoring the Partial Pressure of Brain Tissue Oxygen.
- Publications
- Clinicians' Approaches to Prognostication After Traumatic Brain Injury and Cardiac Arrest: A Multi-Hospital, Qualitative Study.Neurocritical care, 2026
- Brain Oxygen Optimization in Severe Traumatic Brain Injury (BOOST-3): a multicentre, randomised, blinded-endpoint, comparative effectiveness study of brain tissue oxygen and intracranial pressure monitoring versus intracranial pressure alone.BMJ open, 2022
- Record updated
- 12 November 2026